Medical Communications

As Mylan is left reeling from the backlash on its EpiPen price increase in the US, many lost their jobs …

Biogen has announced that its investigational Alzheimer’s disease treatment aducanumab has been granted fast track designation by the FDA. The …

Amgen has announced that the FDA has approved the supplemental Biologics License Application for Blincyto (blinatumomab) in the treatment of …

NICE has issued final draft guidance recommending Bayer’s Xofigo (radium-223 dichloride) for the treatment of prostate cancer. Previously, the drug …

Less than a decade after the company was suspended, Roche has now successfully re-joined the Association of the British Pharmaceutical …

Packaging Equipment Specialist, Sepha, has released a functional upgrade for one of its original products, EZ Blister, the lab scale …

 Originally published in the September edition of Pharmafocus, Matt Fellows investigates how cloud computing may just be the answer the …

Eli Lilly has elected Jamere Jackson to its board of directors, effective 1 October, where he will serve on the …

Recipharm, the contract development and manufacturing organisation (CDMO), announces that it has entered into a long term supply agreement with …

The latest edition of Pharmafocus is available online now. In this issue, we explore the future of the clinical trial …

If this week left you feeling with a sense of déjà vu, you could certainly be forgiven. With US politicians …

Mylan and Biocon have announced that the European Medicines Agency (EMA) has accepted for review its marketing authorisation application for …

Denali Therapeutics has announced a string of collaborations and financing deals worth $130 million that will see the biotech, which …

Takeda has announced plans to close its facility in Cambridge in the UK, to refocus its research and development operations …

Subject to intense pressure over the last few days, Mylan has made an attempt to avoid becoming “another Valeant” by …